التفاصيل البيبلوغرافية
| العنوان: |
PBI87 REAL-WORLD GOLIMUMAB EFFECTIVENESS AND IMPACT ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS OR AXIAL SPONDYLARTHRITIS AND A TREATMENT FAILURE TO PREVIOUS TNFÎ' INHIBITOR THERAPY. |
| المؤلفون: |
Georgiadis, A.1 (AUTHOR), Theodoridou, A.2 (AUTHOR), Vounotrypidis, P.3 (AUTHOR), Zisopoulos, D.4 (AUTHOR), Kallitsakis, I.5 (AUTHOR), Kandyli, A.6 (AUTHOR), Migkos, M.7 (AUTHOR), Bournazos, I.8 (AUTHOR), Sidiropoulos, P.9 (AUTHOR), Efstathiou, M.10 (AUTHOR), Athanassiou, P.11 (AUTHOR), Haratsis, I.12 (AUTHOR), Petrikkou, E.12 (AUTHOR), Vassilopoulos, D.13 (AUTHOR) |
| المصدر: |
Value in Health. 2019 Supplement 3, Vol. 22, pS433-S433. 1p. |
| مصطلحات موضوعية: |
*PSORIATIC arthritis, *RHEUMATOID arthritis, *SPONDYLOARTHROPATHIES, *GOLIMUMAB, *ANKYLOSING spondylitis, *BRAF genes |
| مستخلص: |
To assess the real-world effectiveness of golimumab and its impact on patient-reported outcomes in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or axial spondylarthritis (axSpA). GO-BEYOND is a prospective, 18-month study, in patients with active RA, PsA or axSpA and an inadequate response/intolerability to 1 TNF inhibitor, who are considered for golimumab treatment. Thirty-six patients (RA:13; PsA:10; axSpA:13) with moderate disease activity in all 3 indications were included. [Extracted from the article] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder